C1 inhibitor treatment improves host defense in pneumococcal meningitis in rats and mice

Journal of Infectious Diseases

Volumn 196, Issue 1, 2007, Pages 115-123

  Zwijnenburg, Petra J G ^a,b   Van Der Poll, Tom ^b   Florquin, Sandrine ^b   Polfliet, Machteld M J ^a   Van Den Berg, Timo K ^a,c   Dijkstra, Christine D ^a   Roord, John J ^a   Hack, C Erik ^a,c   Van Furth, A Marceline ^a,b  

^a VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^b UNIVERSITY OF AMSTERDAM   (Netherlands)

^c SANQUIN RESEARCH   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE; COMPLEMENT COMPONENT C1S INHIBITOR; COMPLEMENT COMPONENT C3; CYTOKINE; SANQUIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL MENINGITIS; CELL INFILTRATION; CLINICAL FEATURE; COMPLEMENT ACTIVATION; COMPLEMENT CLASSICAL PATHWAY; COMPLEMENT INHIBITION; COMPLEMENT SYSTEM; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENDOTOXEMIA; HOST RESISTANCE; INNATE IMMUNITY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RAT; SEPSIS; TISSUE INJURY; TREATMENT OUTCOME; TREATMENT RESPONSE; UPREGULATION;

ANIMALS; BRAIN; BRAIN CHEMISTRY; CEREBROSPINAL FLUID; CHEMOKINES; COLONY COUNT, MICROBIAL; COMPLEMENT ACTIVATION; COMPLEMENT C1; COMPLEMENT C1 INHIBITOR PROTEIN; COMPLEMENT PATHWAY, CLASSICAL; CYTOKINES; DISEASE MODELS, ANIMAL; HUMANS; MACROPHAGE-1 ANTIGEN; MALE; MENINGES; MENINGITIS, PNEUMOCOCCAL; MICE; MICE, INBRED C57BL; RATS; RATS, WISTAR; STREPTOCOCCUS PNEUMONIAE;

EID: 34250817675     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/518609     Document Type: Article

References (50)

1. Koedel U, Scheld WM, Pfister HW. Pathogenesis and pathophysiology of pneumococcal meningitis. Lancet Infect Dis 2002; 2:721-36.
2. Cunha BA. Clinical relevance of penicillin-resistant Streptococcus pneumoniae. Semin Respir Infect 2002; 17:204-14.
3. Scheld WM, Koedel U, Nathan B, Pfister HW. Pathophysiology of bacterial meningitis: mechanism(s) of neuronal injury. J Infect Dis 2002; 186(Suppl 2):S225-33.
4. Nau R, Bruck W. Neuronal injury in bacterial meningitis: mechanisms and implications for therapy. Trends Neurosci 2002; 25:38-45.
5. Kirschfink M, Nurnberger W. C1 inhibitor in anti-inflammatory therapy: from animal experiment to clinical application. Mol Immunol 1999; 36:225-32.
6. Stahel PF, Barnum SR. Bacterial meningitis: complement gene expression in the central nervous system. Immunopharmacology 1997; 38:65-72.
7. Barnum SR. Complement biosynthesis in the central nervous system. Crit Rev Oral Biol Med 1995; 6:132-46.
8. Gasque P, Singhrao SK, Neal JW, Gotze O, Morgan BP. Expression of the receptor for complement C5a (CD88) is up-regulated on reactive astrocytes, microglia, and endothelial cells in the inflamed human central nervous system. Am J Pathol 1997; 150:31-41.
9. Wing MC, Seilly DJ, Nicholas RS, et al. Comparison of C1q-receptors on rat microglia and peritoneal macrophages. J Neuroimmunol 1999; 94:74-81.
10. Stahel PF, Frei K, Fontana A, Eugster HP, Ault BH, Barnum SR. Evidence for intrathecal synthesis of alternative pathway complement activation proteins in experimental meningitis. Am J Pathol 1997; 151:897-904.
11. Stahel PF, Nadal D, Pfister HW, Paradisis PM, Barnum SR. Complement C3 and factor B cerebrospinal fluid concentrations in bacterial and aseptic meningitis. Lancet 1997; 349:1886-7.
12. Zwahlen A, Nydegger UE, Vaudaux P, Lambert PH, Waldvogel FA. Complement-mediated opsonic activity in normal and infected human cerebrospinal fluid: early response during bacterial meningitis. J Infect Dis 1982; 145:635-46.
13. Ernst JD, Hartiala KT, Goldstein IM, Sande MA. Complement (C5)-derived chemotactic activity accounts for accumulation of polymorphonuclear leukocytes in cerebrospinal fluid of rabbits with pneumococcal meningitis. Infect Immun 1984; 46:81-6.
14. de Agostini A, Lijnen HR, Pixley RA, Colman RW, Schapira M. Inactivation of factor XII active fragment in normal plasma: predominant role of C-1-inhibitor. J Clin Invest 1984; 73:1542-9.
15. Schapira M, de Agostini A, Schifferli JA, Colman RW. Biochemistry and pathophysiology of human C1 inhibitor: current issues. Complement 1985; 2:111-26.
16. Cai S, Dole VS, Bergmeier W, et al. A direct role for C1 inhibitor in regulation of leukocyte adhesion. J Immunol 2005; 174:6462-6.
17. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE. C1-esterase inhibitor: an anti-inflammatory agent and its potential use in the treatment of diseases other than hereditary angioedema. Pharmacol Rev 2000; 52:91-112.
18. Hack CE, Voerman H J, Eisele B, et al. C1-esterase inhibitor substitution in sepsis. Lancet 1992; 339:378.
19. Caliezi C, Zeerleder S, Redondo M, et al. C1-inhibitor in patients with severe sepsis and septic shock: beneficial effect on renal dysfunction. Crit Care Med 2002; 30:1722-8.
20. Schmidt W, Stenzel K, Gebhard MM, Martin E, Schmidt H. C1-esterase inhibitor and its effects on endotoxin-induced leukocyte adherence and plasma extravasation in postcapillary venules. Surgery 1999; 125:280-7.
21. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, et al. Proteolytic inactivation of plasma C1-inhibitor in sepsis. J Clin Invest 1989; 84:443-50.
22. Zwijnenburg PJ, van der Poll T, Florquin S, van Deventer SJ, Roord JJ, van Furth AM. Experimental pneumococcal meningitis in mice: a model of intranasal infection. J Infect Dis 2001; 183:1143-6.
23. Polfliet MM, Zwijnenburg PJ, van Furth AM, et al. Meningeal and perivascular macrophages of the central nervous system play a protective role during bacterial meningitis. J Immunol 2001; 167:4644-50.
24. Zwijnenburg PJ, Van Der Poll T, Florquin S, Roord JJ, Van Furth AM. Interleukin-10 negatively regulates local cytokine and chemokine production but does not influence antibacterial host defense during murine pneumococcal meningitis. Infect Immun 2003; 71:2276-9.
25. Zwijnenburg PJ, Van Der Poll T, Florquin S, Roord JJ, Van Furth AM. IL-1 receptor type 1 gene-deficient mice demonstrate an impaired host defense against pneumococcal meningitis. J Immunol 2003; 170:4724-30.
26. Koedel U, Bayerlein I, Paul R, Sporer B, Pfister HW. Pharmacologic interference with NF-κB activation attenuates central nervous system complications in experimental pneumococcal meningitis. J Infect Dis 2000; 182:1437-45.
27. de Smet BJ, de Boer JP, Agterberg J, Rigter G, Bleeker WK, Hack CE. Clearance of human native, proteinase-complexed, and proteolytically inactivated C1-inhibitor in rats. Blood 1993; 81:56-61.
28. Bos IG, van Mierlo GJ, Bleeker WK, et al. The potentiation of human C1-inhibitor by dextran sulphate is transient in vivo: studies in a rat model. Int Immunopharmacol 2001; 1:1583-95.
29. de Groot CJ, Dijkstra CD, Sminia T. Discrimination between different types of neuroglial cells in rat central nervous system using combined immuno- and enzyme-histochemical methods. Immunobiology 1988; 178:177-90.
30. Tauber MG, Zwahlen A. Animal models for meningitis. Methods Enzymol 1994; 235:93-106.
31. Walport MJ. Complement: first of two parts. N Engl J Med 2001; 344:1058-66.
32. Fijen CA, Kuijper EJ, te Bulte MT, Daha MR, Dankert J. Assessment of complement deficiency in patients with meningococcal disease in The Netherlands. Clin Infect Dis 1999; 28:98-105.
33. Tuomanen E, Hengstler B, Zak O, Tomasz A. The role of complement in inflammation during experimental pneumococcal meningitis. Microb Pathog 1986; 1:15-32.
34. Koch T, Annuss C, Schiefer HG, van Ackern K, Neuhof H. Impaired bacterial clearance after activation of the complement and coagulation systems. Shock 1997; 7:42-8.
35. Hellwig SM, van Oirschot HF, Hazenbos WL, van Spriel AB, Mooi FR, van De Winkel JG. Targeting to Fcγ receptors, but not CR3 (CD11b/CD18), increases clearance of Bordetella pertussis. J Infect Dis 2001; 183:871-9.
36. Antal JM, Cunningham JV, Goodrum KJ. Opsonin-independent phagocytosis of group B streptococci: role of complement receptor type three. Infect Immun 1992; 60:1114-21.
37. Levi M, Roem D, Kamp AM, de Boer JP, Hack CE, ten Cate JW. Assessment of the relative contribution of different protease inhibitors to the inhibition of plasmin in vivo. Thromb Haemost 1993; 69:141-6.
38. Eberhard T, Kronvall G, Ullberg M. Surface bound plasmin promotes migration of Streptococcus pneumoniae through reconstituted basement membranes. Microb Pathog 1999; 26:175-81.
39. Wyler DJ, Wasserman SI, Karchmer AW. Substances which modulate leukocyte migration are present in CSF during meningitis. Ann Neurol 1979; 5:322-6.
40. Nolan CM, Clark RA, Beaty HN. Experimental pneumococcal meningitis. III. Chemotactic activity in cerebrospinal fluid. Proc Soc Exp Biol Med 1975; 150:134-6.
41. Lahrtz F, Piali L, Spanaus KS, Seebach J, Fontana A. Chemokines and chemotaxis of leukocytes in infectious meningitis. J Neuroimmunol 1998; 85:33-43.
42. Kadurugamuwa JL, Hengstler B, Bray MA, Zak O. Inhibition of complement-factor-5a-induced inflammatory reactions by prostaglandin E2 in experimental meningitis. J Infect Dis 1989; 160:715-9.
43. Cai S, Davis AE III. Complement regulatory protein C1 inhibitor binds to selectins and interferes with endothelial-leukocyte adhesion. J Immunol 2003; 171:4786-91.
44. Jansen PM, Eisele B, de Jong IW, et al. Effect of C1 inhibitor on inflammatory and physiologic response patterns in primates suffering from lethal septic shock. J Immunol 1998; 160:475-84.
45. Czermak BJ, Sarma V, Bless NM, Schmal H, Friedl HP, Ward PA. In vitro and in vivo dependency of chemokine generation on C5a and TNF-alpha. J Immunol 1999; 162:2321-5.
46. Goodman MG, Chenoweth DE, Weigle WO. Induction of interleukin 1 secretion and enhancement of humoral immunity by binding of human C5a to macrophage surface C5a receptors. J Exp Med 1982; 156:912-7.
47. Okusawa S, Yancey KB, van der Meer JW, et al. C5a stimulates secretion of tumor necrosis factor from human mononuclear cells in vitro. Comparison with secretion of interleukin 1 beta and interleukin 1 alpha. J Exp Med 1988; 168:443-8.
48. Couturier C, Haeffner-Cavaillon N, Weiss L, Fischer E, Kazatchkine MD. Induction of cell-associated interleukin 1 through stimulation of the adhesion-promoting proteins LFA-1 (CD11a/CD18) and CR3 (CD11b/CD18) of human monocytes. Eur J Immunol 1990; 20:999-1005.
49. Bacle F, Haeffner-Cavaillon N, Laude M, Couturier C, Kazatchkine MD. Induction of IL-1 release through stimulation of the C3b/C4b complement receptor type one (CR1, CD35) on human monocytes. J Immunol 1990; 144:147-52.
50. Takabayashi T, Vannier E, Burke JF, Tompkins RG, Gelfand JA, Clark BD. Both C3a and C3a(desArg) regulate interleukin-6 synthesis in human peripheral blood mononuclear cells. J Infect Dis 1998; 177:1622-8.